Yesterday, Representatives Carolyn Maloney (D-NY), Jerrold Nadler (D-NY) and David Cicilline (D-RI) asked Federal Trade Commission (FTC) Acting Chair Rebecca Kelly Slaughter to open a formal inquiry into pharmaceutical company AbbVie’s practices, which the representatives said have worked “to delay U.S. biosimilar entry for [AbbVie’s] blockbuster drug Humira.” The request was prompted by documents uncovered as part of an investigation being conducted by the House Committee on Oversight and Reform into the company. “Based on our review, these documents indicate that AbbVie delayed biosimilar competition for far longer than warranted by its own internal evaluations of the strength of its patent portfolio, which anticipated biosimilar entry no later than 2017,” said the letter.
Patent
- Enablement
- Fee Shifting
- Litigation
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?
- A Kinder, Gentler ‘Death Squad’: Ten Years in, Despite Some Reforms, the USPTO is Still Killing U.S. Patents
Recent Posts
- Looming Leahy Bill Would End Fintiv Practice at PTAB
- Patent Filings Roundup: Trio of Actions Accuse IP Investments of Coordinated Campaign with Intellectual Ventures Backend; Judge Albright Cancels One of 141 WSOU-Asserted Patents; New Magnetar Entity Surfaces
- International: WIPO Reports Increasing Prevalence of Alternative Dispute Resolution for Business-to-Business Copyright Disputes
- New Tillis-Leahy Bills to Boost Innovation: The Good, the Bad and the Nonsense
- Where Have All of the Ex Parte Appeals Gone?